Quality of nuchal translucency measurements in the Netherlands: A quantitative analysis

Ultrasound in Obstetrics and Gynecology

Volumn 34, Issue 2, 2009, Pages 136-141

  Koster, M P H ^a,b   Wortelboer, E J ^b   Engels, M A J ^c   Stoutenbeek, P H ^b   Elvers, L H ^a   Visser, G H A ^b   Schielen, P C J I ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Down syndrome; Nuchal translucency; Prenatal screening; Quality assurance

Indexed keywords

ARTICLE; CALCULATION; CROWN RUMP LENGTH; DIAGNOSTIC ACCURACY; DOWN SYNDROME; EVALUATION; FALSE POSITIVE RESULT; HUMAN; MONITORING; NETHERLANDS; NUCHAL TRANSLUCENCY MEASUREMENT; OCCUPATIONAL HEALTH SERVICE; OPERATOR; PRIORITY JOURNAL; PUBLISHING; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REFERENCE DATABASE; RETROSPECTIVE STUDY; SCREENING;

DOWN SYNDROME; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; NETHERLANDS; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY TRIMESTER, FIRST; QUALITY ASSURANCE, HEALTH CARE;

EID: 68149158701     PISSN: 09607692     EISSN: 14690705     Source Type: Journal    
DOI: 10.1002/uog.6398     Document Type: Article

References (22)

1. Wald NJ, Kennard A, Hackshaw A, McGuire A. Antenatal screening for Down's syndrome. J Med Screening 1997; 4: 181-246.
2. Cuckle HS, Arbuzova S. Multimarker serum screening for chromosomal abnormalities. In GeneticDisorders and the Fetus; Diagnosis, Prevention and Treatment, Milunsky A (ed.). Johns Hopkins University Press: Baltimore, 2004; 795-835.
3. Dutch Health Council. Prenatal screening: Down syndrome, neural tube defects, routine ultrasound. (In Dutch). Den Haag: Health Council 2001; publication nr. 2001/11.
4. Dutch Health Council. Prenatal screening (2): Down syndrome, neural tube defects, routine ultrasound. (In Dutch). Den Haag: Health Council 2004; publication nr. 2004/2006.
5. Letter 'Organisation of prenatal screening' (ref CZ/IZ-2612095) from the State Secretary of Health, Welfare and Sports to the chairman of the Dutch Lower Chamber.
6. National quality demands of sonographers (version 3).Working Group for Quality Health Performance. December 2006.
7. Crossley JA, Aitken DA, Cameron AD, McBride E, Connor JM. Combined ultrasound and biochemical screening for Down's syndrome in the first trimester: a Scottish multicentre study. BJOG 2002; 109: 667-676. (Pubitemid 37329279)
8. Schielen PCJI, van Leeuwen-Spruijt M, Belmouden I, Elvers LH, Jonker M, Loeber JG. Multi-centre first-trimester screening for Down syndrome in the Netherlands in routine clinical practice. Prenat Diagn 2006; 26: 711-718. (Pubitemid 44252249)
9. Van den Berg M, Kleinveld JH, Sander MJ, van Vugt JMG, Timmermans DRM. Quality of nuchal translucency measurements: an exploratory study into their performance and evaluation (In Dutch). Ned Tijdschr Geneeskd 2005; 149: 1691-1696.
10. Herman A, Maymon R, Dreazen E, Caspi E, Bukovsky I,Weinraub Z. Nuchal translucency audit: a novel image-scoring method. Ultrasound Obstet Gynecol 1998; 12: 398-403. (Pubitemid 29034208)
11. Nicolaides KH, Snijders RJ, Cuckle HS. Correct estimation parameters for ultrasound nuchal translucency screening. Prenat Diagn 1998; 18: 519-523.
12. Spencer K, Cicero S, Atzei A, Otigbah C, Nicolaides KH. The influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimestermaternal serum biochemical markers of aneuploidy. Prenat Diagn 2005; 25: 927-929. (Pubitemid 41494989)
13. Palomaki GE, Neveux LM, Donnenfeld A, Lee JES, McDowell G, Canick JA, Summers A, Lambert-Messerlian G, Kellner LH, Zebelman A, Haddow JE. Quality assessment of routine nuchal translucency measurements: a North American laboratory perspective. Genet Med 2008; 10: 131-138. (Pubitemid 351271725)
14. Santiago JC, Ramos-Corpas D. Delta-NT and center-specific ultrasound nuchal translucency medians. Ultrasound Obstet Gynecol 2007; 30: 934-940.
15. D'Alton ME, Cleary-Goldman J. Education and quality review for nuchal translucency ultrasound. Semin Perinatol 2005; 29: 380-385.
16. Logghe H, Cuckle H, Sehmi I. Centre-specific ultrasound nuchal translucency medians needed for Down syndrome screening. Prenat Diagn 2003; 23: 389-392. (Pubitemid 36596968)
17. Schielen PCJI, van Leeuwen M. NT as a parameter for risk estimation. DS News 2006; 1: 45.
18. Registration list Assessment Nuchal Translucency. Fetal Medicine FoundationNetherlands.http://www.fetalmedicine.nl/database2.php. [Accessed 19 December 2006].
19. Spencer K, Bindra R, Nix AB, Heath V, Nicolaides KH. Delta-NT or NT MoM: which is the most appropriate method for calculating accurate patient-specific risks for trisomy 21 in the first trimester? Ultrasound Obstet Gynecol 2003; 22: 142-148. (Pubitemid 36976380)
20. Wapner R, Thom E, Simpson JL, Pergament E, Silver R, Filkins K, Platt L, Mahoney M, Johnson A, Hogge WA, Wilson RD, Mohide P, Hershey D, Krantz D, Zachary J, Snijders R, Greene N, Sabbagha R, MacGregor S, Hill L, Gagnon A, Hallahan T, Jackson L. First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. First-trimester screening for trisomies 21 and 18. N Engl JMed 2003; 349: 1405-1413.
21. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. SURUSS Research Group. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol Assess 2003; 7: 1-77. (Pubitemid 36526776)
22. Wright D, Kagan KO, Molina FS, Gazzoni A, Nicolaides KH. A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol 2008; 31: 376-383.